These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8620669)

  • 21. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
    Li F; Chordia MD; Woodling KA; Macdonald TL
    Chem Res Toxicol; 2007 Dec; 20(12):1854-61. PubMed ID: 17944539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding of nonsteroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin.
    Diana FJ; Veronich K; Kapoor AL
    J Pharm Sci; 1989 Mar; 78(3):195-9. PubMed ID: 2724076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis.
    Wanwimolruk S; Birkett DJ; Brooks PM
    Clin Pharmacokinet; 1982; 7(1):85-92. PubMed ID: 7075085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma protein binding and interaction studies with benoxaprofen.
    Chatfield DH; Green JN; Kao JC; Tarrant ME; Woodage TJ
    Biochem Pharmacol; 1978 Mar; 27(6):887-90. PubMed ID: 656137
    [No Abstract]   [Full Text] [Related]  

  • 26. Stereoselective, competitive, and nonlinear plasma protein binding of ibuprofen enantiomers as determined in vivo in healthy subjects.
    Paliwal JK; Smith DE; Cox SR; Berardi RR; Dunn-Kucharski VA; Elta GH
    J Pharmacokinet Biopharm; 1993 Apr; 21(2):145-61. PubMed ID: 8229677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of fluvastatin to blood cells and plasma proteins.
    Tse FL; Nickerson DF; Yardley WS
    J Pharm Sci; 1993 Sep; 82(9):942-7. PubMed ID: 8229693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
    Rohatagi S; Luo Y; Shen L; Guo Z; Schemm C; Huang Y; Chen K; David M; Nave R; King SP
    Am J Ther; 2005; 12(3):201-9. PubMed ID: 15891262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
    Awni WM; Locke C; Dube LM; Cavanaugh JH
    J Clin Pharmacol; 1997 May; 37(5):388-94. PubMed ID: 9156371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
    Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G
    Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
    Sweeny DJ; Nellans HN
    Drug Metab Dispos; 1995 Jan; 23(1):149-53. PubMed ID: 7720519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.
    Awni WM; Wong S; Chu SY; Patterson K; Hansen R; Machinist JM; Drajesk J; Keane WF; Halstenson CE
    J Clin Pharmacol; 1997 May; 37(5):395-404. PubMed ID: 9156372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
    Awni WM; Granneman GR; Locke CS; Brandwein SR; Dube LM
    Eur J Clin Pharmacol; 1995; 48(2):155-60. PubMed ID: 7589031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competition between salicylate and other drugs in binding to human serum protein in vitro.
    Muirden KD; Deutschman P; Phillips M
    Aust N Z J Med; 1974 Apr; 4(2):149-53. PubMed ID: 4528482
    [No Abstract]   [Full Text] [Related]  

  • 35. Displacement of valproic acid and carbamazepine from protein binding in normal and uremic sera by tolmetin, ibuprofen, and naproxen: presence of inhibitor in uremic serum that blocks valproic acid-naproxen interactions.
    Dasgupta A; Volk A
    Ther Drug Monit; 1996 Jun; 18(3):284-7. PubMed ID: 8738769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.
    McLachlan AJ; Cutler DJ; Tett SE
    Eur J Clin Pharmacol; 1993; 44(5):481-4. PubMed ID: 8359187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
    J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereoselective pharmacokinetics of ibuprofen in rats: effect of enantiomer-enantiomer interaction in plasma protein binding.
    Itoh T; Maruyama J; Tsuda Y; Yamada H
    Chirality; 1997; 9(4):354-61. PubMed ID: 9275314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma.
    Wenzel SE; Kamada AK
    Ann Pharmacother; 1996; 30(7-8):858-64. PubMed ID: 8826571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.